Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions

Phase 1

Conditions: Cardiovascular Diseases

Interventions: Drug: Reference drug
Drug: Test drug 1
Drug: Test drug 2

First Posted Date: 2020-12-03

Last Posted Date: 2020-12-03

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT04651881

Locations: 🇰🇷
Central Hospital, Gyeonggi-do, Siheung-si, Korea, Republic of

A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of CKD-333 or Co-administration of CKD-333 and D085 in Healthy Volunteers

Phase 1

Conditions: Cardiovascular Diseases

Interventions: Drug: CKD-330 1 Tab. and D085 1 Tab.
Drug: CKD-333 1 Tab

First Posted Date: 2020-11-13

Last Posted Date: 2020-11-13

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 51

Registration Number: NCT04627207

A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Nafamostat Mesilate

First Posted Date: 2020-11-13

Last Posted Date: 2021-08-13

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 13

Registration Number: NCT04628143

Locations: 🇰🇷
Korea Cancer Center Hospital, Seoul, Korea, Republic of

A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Nafamostat Mesilate

First Posted Date: 2020-11-10

Last Posted Date: 2021-02-02

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 104

Registration Number: NCT04623021

Locations: 🇷🇺
A108_02CVD2014 Site# 29, St. Petersburg, Russian Federation
🇷🇺
A108_02CVD2014 Site# 3, St. Petersburg, Russian Federation
🇷🇺
A108_02CVD2014 Site# 31, Ryazan, Russian Federation

and more 8 locations

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers

Phase 1

Conditions: Cardiovascular Disease

Interventions: Drug: CKD-330 Tab. and D090 Tab.
Drug: CKD-333 Tab.

First Posted Date: 2020-11-02

Last Posted Date: 2020-11-02

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 51

Registration Number: NCT04611932

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348

Phase 1

Completed

Conditions: Hypertension and Dyslipidemia

Interventions: Drug: CKD-348
Drug: CKD-828, D097, D337

First Posted Date: 2020-10-14

Last Posted Date: 2021-02-04

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 62

Registration Number: NCT04587206

Locations: 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of

Study to Evaluate the Efficacy and Safety of CKD-352

Phase 3

Completed

Conditions: Dry Eye Disease

Interventions: Drug: CKD-352
Drug: Diquafosol Sodium 3%

First Posted Date: 2020-09-14

Last Posted Date: 2021-06-01

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 283

Registration Number: NCT04548427

Locations: 🇰🇷
Pusan National University Hospital, Pusan, Korea, Republic of

Clinical Trial to Evaluate the Efficacy and Safety of TenofoBell® Tablet in Chronic Hepatitis B Patients

Phase 4

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Experimental

First Posted Date: 2020-09-07

Last Posted Date: 2021-07-28

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 78

Registration Number: NCT04539652

Locations: 🇰🇷
Daegu Chatholic University Medical center, Daegu, Korea, Republic of

A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Cantabell Tab
Drug: Candemore Plus Tab

First Posted Date: 2020-08-20

Last Posted Date: 2020-08-20

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 132

Registration Number: NCT04521023

Locations: 🇰🇷
Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of
🇰🇷
Jeju National University Hospital, Jeju, Korea, Republic of
🇰🇷
Daegu Catholic Univ. Medical Center, Daegu, Korea, Republic of

and more 11 locations

Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg

Phase 4

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Lipilou®(generic atorvastatin drug) 20 mg
Drug: Lipilou®(generic atorvastatin drug) 10 mg

First Posted Date: 2020-08-12

Last Posted Date: 2020-08-12

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 250

Registration Number: NCT04511000

Locations: 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷
Sejong General Hospital, Bucheon, Korea, Republic of

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy